A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Trial Details

NCT ID

NCT05420779

Phase

PHASE2

Sponsor

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

• TSL-1502 capsules(low dose)
• TSL-1502 capsules(high dose)
• Investigator's choice of chemotherapy

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• 1\) Agree to follow the clinical trial protocol, volunteer, and sign the informed consent form (ICF).
• 2\) Women aged ≥ 18 years and ≤ 75 years at the date of signing the ICF. 3) HER2-locally advanced breast cancer diagnosed by histopathology and/or …
• 4\) Prior platinum therapy is allowed, but the best response to platinum therapy is required to be CR, PR, or persistent ≥ 12 weeks SD. If given as…
• 5\) Hormone receptor-positive patients need to have received at least first-line of endocrine therapy for locally advanced or metastatic breast can…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.